Published in J Natl Cancer Inst on May 06, 1998
Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A (2003) 6.35
The molecular pathology of breast cancer progression. J Pathol (2010) 1.65
Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma. Am J Pathol (2004) 1.44
High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol (2001) 1.36
Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer. J Mammary Gland Biol Neoplasia (2010) 1.32
WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res (2003) 1.28
Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. Am J Pathol (2000) 1.28
Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer. Breast Cancer Res (2005) 1.23
The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res (2003) 1.20
Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors. BMC Cancer (2010) 1.20
Estrogen signaling and the DNA damage response in hormone dependent breast cancers. Front Oncol (2014) 1.18
Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr (2010) 1.16
Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila) (2014) 1.13
Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer. Genes Chromosomes Cancer (2008) 1.10
Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression. Am J Pathol (2012) 1.09
Preinvasive breast cancer. Annu Rev Pathol (2010) 1.08
Early dysregulation of cell adhesion and extracellular matrix pathways in breast cancer progression. Am J Pathol (2009) 1.07
GSTP1 promoter hypermethylation is an early event in breast carcinogenesis. Virchows Arch (2007) 1.05
Allelic loss on chromosome band 18p11.3 occurs early and reveals heterogeneity in breast cancer progression. Breast Cancer Res (2001) 1.04
Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma. World J Surg Oncol (2007) 0.99
The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions. Breast Cancer Res (2003) 0.99
Genomic approaches in the management and treatment of breast cancer. Br J Cancer (2005) 0.97
Genome-wide analysis of interferon regulatory factor I binding in primary human monocytes. Gene (2011) 0.96
Loss of heterozygosity in fibrocystic change of the breast: genetic relationship between benign proliferative lesions and associated carcinomas. Am J Pathol (2000) 0.94
Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation. Breast Cancer Res (2007) 0.93
Genomewide scan for loss of heterozygosity and chromosomal amplification in breast carcinoma using single-nucleotide polymorphism arrays. Cancer Genet Cytogenet (2008) 0.93
Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group. Am J Pathol (2009) 0.93
Lobular and ductal intraepithelial neoplasia. Pathologe (2008) 0.93
A shared transcriptional program in early breast neoplasias despite genetic and clinical distinctions. Genome Biol (2014) 0.91
Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast. Genes Chromosomes Cancer (2012) 0.90
PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma. Clin Cancer Res (2014) 0.89
Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Res (2003) 0.89
Assessment of DNA methylation status in early stages of breast cancer development. Br J Cancer (2013) 0.88
Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer. Mol Pathol (2001) 0.87
Re-evaluating early breast neoplasia. Breast Cancer Res (2008) 0.85
Flat epithelial atypia with and without atypical ductal hyperplasia: to re-excise or not. Results of a 5-year prospective study. Virchows Arch (2012) 0.85
Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer. Breast Cancer Res (2015) 0.84
Genomic instability demonstrates similarity between DCIS and invasive carcinomas. Breast Cancer Res Treat (2008) 0.84
Discrepancies in the diagnosis of intraductal proliferative lesions of the breast and its management implications: results of a multinational survey. Virchows Arch (2006) 0.82
Proliferating activity in columnar cell lesions of the breast. Virchows Arch (2006) 0.81
Biologic characteristics of premalignant breast disease. Cancer Biomark (2010) 0.81
Telomeres in cancer: tumour suppression and genome instability. Nat Rev Mol Cell Biol (2017) 0.80
Molecular classification of breast cancer. Virchows Arch (2014) 0.80
Intraductal proliferative lesions of the breast-terminology and biology matter: premalignant lesions or preinvasive cancer? Int J Surg Oncol (2012) 0.80
Ductal carcinoma in situ: a rose by any other name. J Natl Cancer Inst (2013) 0.80
Short-term prophylactic tamoxifen reduces the incidence of antiestrogen-resistant/estrogen receptor-positive/progesterone receptor-negative mammary tumors. Cancer Prev Res (Phila) (2009) 0.79
Heterogeneity Between Ducts of the Same Nuclear Grade Involved by Duct Carcinoma In Situ (DCIS) of the Breast. Cancer Inform (2010) 0.79
Heterogeneity of invasive ductal carcinoma: proposal for a hypothetical classification. J Korean Med Sci (2006) 0.78
Multiplex genotype analysis of invasive carcinoma and accompanying proliferative lesions microdissected from breast tissue. J Mol Diagn (2000) 0.78
miRNAs as potential biomarkers in early breast cancer detection following mammography. Cell Biosci (2016) 0.77
Evidence of a genomic biomarker in normal human epithelial mammary cell line, MCF-10A, that is absent in the human breast cancer cell line, MCF-7. J Biomed Biotechnol (2006) 0.77
Investigational Paradigms in Downscoring and Upscoring DCIS: Surgical Management Review. Int J Surg Oncol (2012) 0.77
Ductal Carcinoma In Situ of the Breast. Indian J Surg (2013) 0.76
Cancer stem cells and early stage basal-like breast cancer. World J Obstet Gynecol (2016) 0.75
Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer. Biomark Cancer (2015) 0.75
Genes involved in breast cancer progression: analysis of global changes in gene expression or retroviral tagging? Am J Pathol (2002) 0.75
Examining the Relationship between Pre-Malignant Breast Lesions, Carcinogenesis and Tumor Evolution in the Mammary Epithelium Using an Agent-Based Model. PLoS One (2016) 0.75
[The significance of "normal tissue" in the development of breast cancer: new concepts of early carcinogenesis]. Pathologe (2006) 0.75
[Atypical ductal hyperplasia and atypical epithelial proliferation of ductal type]. Pathologe (2009) 0.75
Multicolor immunofluorescence reveals that p63- and/or K5-positive progenitor cells contribute to normal breast epithelium and usual ductal hyperplasia but not to low-grade intraepithelial neoplasia of the breast. Virchows Arch (2017) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol (1998) 11.84
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 11.18
REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer (2005) 4.85
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 4.67
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst (1993) 4.45
Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst (1994) 4.28
Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst (2000) 4.26
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat (1992) 3.63
Aberrant subcellular localization of BRCA1 in breast cancer. Science (1995) 3.61
Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med (1992) 3.55
Cathepsin D and prognosis in breast cancer. N Engl J Med (1990) 3.43
The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer (1980) 3.34
HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol (1989) 2.96
Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer (2001) 2.71
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst (1999) 2.58
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A (1998) 2.55
Speech perception as a function of electrical stimulation rate: using the Nucleus 24 cochlear implant system. Ear Hear (2000) 2.51
Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol (1993) 2.42
Evaluation of a new spectral peak coding strategy for the Nucleus 22 Channel Cochlear Implant System. Am J Otol (1994) 2.37
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem (2001) 2.16
HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res (1990) 2.14
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res (1985) 2.13
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol (1987) 2.12
Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem (2001) 2.07
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer (2000) 2.05
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol (1992) 2.05
Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst (1992) 2.05
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol (1999) 2.00
Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst (1993) 1.99
Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst (1993) 1.95
How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst (1990) 1.95
Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol (1999) 1.89
The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J (1994) 1.87
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res (2000) 1.86
Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat (1998) 1.85
Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst (1991) 1.84
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol (1984) 1.84
An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res (1997) 1.82
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol (1995) 1.81
Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr (1994) 1.79
Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med (1983) 1.79
Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst (1994) 1.77
Estrogen receptor and breast cancer. Semin Cancer Biol (2001) 1.77
Epidemiology of an international outbreak of Salmonella agona. Lancet (1973) 1.76
DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer (1988) 1.75
Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ (1995) 1.75
Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst (1999) 1.75
MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res (1997) 1.74
Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat (1992) 1.74
Estrogen receptor variants in clinical breast cancer. Mol Endocrinol (1991) 1.73
Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int J Cancer (1998) 1.72
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med (1989) 1.70
Intracochlear factors contributing to psychophysical percepts following cochlear implantation. Acta Otolaryngol (1998) 1.68
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol (1994) 1.67
Electrical stimulation of the auditory nerve: the effect of electrode position on neural excitation. Hear Res (1993) 1.66
Variation in speech perception scores among children with cochlear implants. Ear Hear (2001) 1.64
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol (2005) 1.63
Evaluation of methods for isolating Salmonella and Arizona organisms from pet turtles. Appl Microbiol (1974) 1.62
Clinical findings for a group of infants and young children with auditory neuropathy. Ear Hear (1999) 1.60
Changing distribution of primary cancers in the large bowel. JAMA (1977) 1.59
p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res (1993) 1.59
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet (1996) 1.58
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res (1988) 1.57
Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. J Biol Chem (1999) 1.57
Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest (1989) 1.56
Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol (1999) 1.55